Activin receptor type-1-like · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Activin receptor type-1-like shows clinical signal disease relevance led by hepatocellular carcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P37023. Start with hepatocellular carcinoma, then reuse UniProt P37023 as the stable protein anchor across project notes and exports.
Start with hepatocellular carcinoma, then reuse UniProt P37023 as the stable protein anchor across project notes and exports.
Activin receptor type-1-like shows clinical signal disease relevance led by hepatocellular carcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with hepatocellular carcinoma because it currently carries clinical signal support. Linked drugs include ASCRINVACUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyActivin receptor type-1-like
Review this target as Activin receptor type-1-like, mapped to UniProt P37023. Sequence length is 503 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Activin receptor type-1-like as ChEMBL target CHEMBL5311, mapped to UniProt P37023. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Activin receptor type-1-like is the right protein anchor across sources, using UniProt P37023 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why hepatocellular carcinoma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Activin receptor type-1-like |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P37023 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Activin receptor type-1-like |
| UniProt Accession | P37023 |
| Component Type | Protein |
| Sequence Length | 503 aa |
Activin receptor type-1-like
Review this target as Activin receptor type-1-like, mapped to UniProt P37023. Sequence length is 503 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Activin receptor type-1-like shows clinical signal disease relevance led by hepatocellular carcinoma. 4 more disease programs remain visible in the same review block.
Start review with hepatocellular carcinoma because it currently carries clinical signal support. Linked drugs include ASCRINVACUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3667966 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3667990 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3818173 | 8.96 | IC50 | 1.1 | Preclinical |
| CHEMBL3667999 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL3667967 | 8.89 | IC50 | 1.3 | Preclinical |
| CHEMBL1980995 | 8.87 | IC50 | 1.361 | Preclinical |
| CHEMBL1230714 | 8.74 | IC50 | 1.8 | Preclinical |
| CHEMBL3668000 | 8.72 | IC50 | 1.9 | Preclinical |
| CHEMBL3667973 | 8.72 | IC50 | 1.9 | Preclinical |
| CHEMBL3667963 | 8.7 | IC50 | 2.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 152 | 359 | 6.4 |
| assay format | 19 | 6 | 8.1 |
| cell-based format | 8 | 3 | 7.4 |
| subcellular format | 1 | 1 | 7.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 2 | 29 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 1 | 7.8 |